At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Integration combines benefits of BioFlux physiological cell interaction analysis with the compactness of the Etaluma Lumascope
August 13, 2015 – (South San Francisco, CA) Today Fluxion Biosciences and Etaluma announced a co-marketing agreement between the two companies. The agreement joins the power of Fluxion’s Bioflux System for cellular assays with Etaluma’s next generation Lumascope inverted microscopes, in applications where space limitations are of importance. Together, these products provide a powerful turnkey solution for live cell assays under physiological flow conditions, in incubators, hoods and hypoxic chambers. One example is the study of biofilm formation by obligate anaerobes, e.g. Clostridium difficile. BioFlux provides tightly controlled laminar flow for up to 96 simultaneous biofilm formation assays. Lumascope permits the direct kinetic observation of the growing biofilm in these assays. Together, the two instruments occupy less than 2 sq. ft. (0.18 m2) of bench space and are easily accommodated by most anaerobic containment apparatus.
“We are excited to be working with Etaluma on imaging our Bioflux assay plates due to the Lumascope’s near diffraction-limited resolution, extensive versatility and affordable price. The Lumascope’s many capabilities, including imaging from 2.5x to 100x in up to three fluorescent channels or brightfield, allows the capture of maximum information content for our customers,” offered John Battista, Director of Sales at Fluxion.
“Fluxion provides best-in-class microfluidic solutions for the study of mammalian or bacterial cells under shear flow conditions. They are a perfect partner for us due to the wide adoption of the BioFlux platform across a number of cell-based assays,” said Chris Shumate, CEO of Etaluma.
About Fluxion Biosciences, Inc.
Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for circulating tumor cell analysis. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
About Etaluma, Inc.
Etaluma’s Lumascopes constitute a dramatic new concept in digital fluorescence microscopy that combines high resolution, multiple formats including time-lapse video and live video, and use with a wide range of labware. Power, control and image capture occur via USB connection directly to a computer. Providing true next-gen microscopy, the compact design allows live cell imaging in incubators, hoods, and other challenging locations. For more information about Etaluma, visit www.etaluma.com.